Adverum Biotechnologies Dirección

Dirección controles de criterios 3/4

El CEO de Adverum Biotechnologies es Laurent Fischer , nombrado en Jun 2020, tiene una permanencia de 4.42 años. compensación anual total es $1.55M, compuesta por 43.4% salario y 56.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.34% de las acciones de la empresa, por valor de $532.33K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 4.5 años, respectivamente.

Información clave

Laurent Fischer

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	43.4%
Permanencia del CEO	4.4yrs
Participación del CEO	0.3%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Laurent Fischer en comparación con los beneficios de Adverum Biotechnologies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$94m
Jun 30 2024	n/a	n/a	-US$100m
Mar 31 2024	n/a	n/a	-US$113m
Dec 31 2023	US$2m	US$672k	-US$117m
Sep 30 2023	n/a	n/a	-US$126m
Jun 30 2023	n/a	n/a	-US$133m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$3m	US$646k	-US$155m
Sep 30 2022	n/a	n/a	-US$156m
Jun 30 2022	n/a	n/a	-US$154m
Mar 31 2022	n/a	n/a	-US$155m
Dec 31 2021	US$9m	US$621k	-US$146m
Sep 30 2021	n/a	n/a	-US$149m
Jun 30 2021	n/a	n/a	-US$138m
Mar 31 2021	n/a	n/a	-US$123m
Dec 31 2020	US$22m	US$327k	-US$118m

Compensación vs. Mercado: La compensación total de Laurent($USD1.55M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD731.63K).

Compensación vs. Ingresos: La compensación de Laurent ha sido consistente con los resultados de la empresa en el último año.

CEO

Laurent Fischer (60 yo)

4.4yrs

Permanencia

US$1,546,477

Compensación

Dr. Laurent Fischer, M.D., serves as Chair of the Board of Teal Omics Inc. He has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He is Advisor of FORM Life Ventures. He...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Laurent Fischer	President	4.4yrs	US$1.55m	0.34% $ 532.3k
Linda Rubinstein	CFO, Principal Financial Officer & Principal Accounting Officer	1.9yrs	US$2.30m	0.048% $ 75.6k
Kishor Soparkar	Chief Operating Officer	3.4yrs	US$903.02k	0.13% $ 210.1k
Setareh Seyedkazemi	Chief Development Officer	2.8yrs	US$799.36k	0.026% $ 40.6k
Rabia Ozden	Chief Medical Officer	less than a year	US$94.20k	0% $ 0
R. Ramelmeier	Chief Technology Officer	1.3yrs	sin datos	sin datos
Romuald Corbau	Chief Scientific Officer	less than a year	sin datos	sin datos
John Rakow	Senior VP & General Counsel	3.3yrs	US$1.33m	0.031% $ 49.0k
Dena House	Chief People Officer	5.3yrs	sin datos	sin datos
Carla Fiankan	Senior Vice President of Regulatory Affairs	2.8yrs	sin datos	sin datos
Michael Steel	Senior Vice President of Quality	3.1yrs	sin datos	sin datos
Heikki Jouttijarvi	Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operations	no data	sin datos	sin datos

2.8yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0HA3 se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Laurent Fischer	President	4.4yrs	US$1.55m	0.34% $ 532.3k
James Scopa	Independent Director	5.5yrs	US$111.70k	0.050% $ 78.1k
Scott Whitcup	Independent Director	4.6yrs	US$106.70k	0% $ 0
David Boyer	Scientific Advisory Board Member	no data	sin datos	sin datos
C. Machado	Independent Chairman	7.7yrs	US$163.80k	0.042% $ 66.7k
Jeffrey Heier	Scientific Advisory Board Member	no data	sin datos	sin datos
Reed Tuckson	Independent Director	3.8yrs	US$99.20k	0% $ 0
Dawn Svoronos	Independent Director	3.9yrs	US$106.70k	0.024% $ 37.8k
Mark Lupher	Independent Director	5.5yrs	US$99.20k	0.062% $ 98.3k
Charles Wykoff	Scientific Advisory Board Member	no data	sin datos	sin datos
Arshad Khanani	Scientific Advisory Board Member	no data	sin datos	sin datos
Szilard Kiss	Director	less than a year	sin datos	sin datos

4.5yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de 0HA3 se considera experimentada (4.5 años de antigüedad promedio).

Adverum Biotechnologies Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Recent updates

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold US$109k worth of stock

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Independent Chairman recently bought US$99k worth of stock

Lexeo Therapeutics, LLC Announces License Agreement with Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc. Appoints Reed V. Tuckson as an Independent Member to Board of Directors

Adverum Biotechnologies, Inc. Appoints Christopher J. Derespino as Chief Business Officer

Adverum Biotechnologies, Inc. Appoints Leone Patterson as Principal Financial Officer and Principal Accounting Officer

Independent Chairman recently bought US$115k worth of stock

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME

Adverum Biotechnologies, Inc Appoints Dawn Svoronos as Independent Member of Board of Directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad